Highly chiral muscarinic ligands: The discovery of (2S,2′R,3′S, 5′R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M2 partial agonist

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 1925-1931

  Scapecchi, Serena ^a   Matucci, Rosanna ^a   Bellucci, Cristina ^a   Buccioni, Michela ^b   Dei, Silvia ^a   Guandalini, Luca ^a   Martelli, Cecilia ^a   Manetti, Dina ^a   Martini, Elisabetta ^a   Marucci, Gabriella ^b   Nesi, Marta ^a   Romanelli, Maria Novella ^a   Teodori, Elisabetta ^a   Gualtieri, Fulvio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 2 (2 METHYL 1,3 OXATHIOLAN 5 YL)PYRROLIDINE 3 SULFOXIDE METHYL IODIDE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHIRALITY; CHO CELL; DIASTEREOISOMER; DRUG RECEPTOR BINDING; ENANTIOMER; GUINEA PIG; HEART ATRIUM; NONHUMAN; STEREOCHEMISTRY;

ANIMALS; ATRIAL FUNCTION, LEFT; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC S-OXIDES; GUINEA PIGS; HUMANS; ILEUM; LIGANDS; LUNG; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PYRROLIDINES; RABBITS; RECEPTOR, MUSCARINIC M2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 33645406084     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0510878     Document Type: Article

References (37)

1. Caulfield, M. P. Muscarinic receptors-Characterization, coupling and function. Pharmacol. Ther. 1993, 58, 319-379.
2. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h-alfa2beta2, h-alfa2beta4, h-alfa3 beta2, h-alfa4beta2, h-alfa4beta4 and h-alfa7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280, 346-356.
3. Korczyn, A. D. Muscarinic M1 agonists in the treatment of Alzheimer's disease. Exp. Opin. Invest. Drugs 2000, 9, 2259-2267.
4. Eisenach, J. C. Muscarinic-mediated analgesia. Life Sci. 1999, 64, 549-554.
5. Dean, B.; Bymaster, F. P.; Scarr, E. Muscarinic receptors in schizofrenia. Curr. Mol. Med. 2003, 3, 419-426.
6. Bartus, R. T. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 2000, 163, 495-529.
7. Gualtieri, F. Cholinergic receptors and neurodegenerative diseases. Receptor Chemistry Towards the Third Millennium: Elsevier Science B.V.: Amsterdam, 2000; pp 85-89.
8. Angeli, P. Pentatomic cyclic agonists and muscarinic receptors: A 20 years review. Farmaco 1995, 50, 565-577.
9. Dei, S.; Bellucci, C.; Buccioni, M.; Ferraroni, M.; Gualtieri, F.; Guandalini, L.; Manetti, D.; Matucci, R.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. Synthesis and cholinergic affinity of diastereomeric and enantiomeric isomers of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine, 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine and of their iodomethylates. Bioorg. Med. Chem. 2003, 11, 3153-3164.
10. Hulme, E. C.; Lu, Z.-L.; Bee, M.; Curtis, C. A. M.; Saldanha, J. The conformational switch in muscarinic acetylcholine receptors. Life Sci. 2001, 68, 2495-2500.
11. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: The transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
12. Dei, S.; Angeli, P.; Bellucci, C.; Buccioni, M.; Gualtieri, F.; Marucci, G.; Manetti, D.; Matucci, R.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. Muscarinic subtypes affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3- oxathiolan-5-yl)pyrrolidine derivatives. Biochem. Pharmacol. 2005, 69, 1637-1645.
13. Arisawa, M.; Takahashi, M.; Takezawa, E.; Yamaguchi, T.; Torisawa, Y.; Nishida, A.; Nakagawa, M. Construction of chiral 1,2-cycloalkanopyrrolidines from L-proline using ring closing metathesis (RCM). Chem. Pharm. Bull. 2000, 48, 1593-1596.
14. Izquierdo, I.; Plaza, M. T.; Tamayo, J. A. Polyhydroxylated pyrrolizidines. Part 5: Stereoselective synthesis of 1,2-dihydroxypyrrolizidines as a model for the preparation of densely polyhydroxylated pyrrolizidines. Tetrahedron: Asymmetry 2004, 15, 3635-3642.
15. Scapecchi, S.; Marucci, G.; Angeli, P.; Bellucci, C.; Dei, S.; Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Teodori, E. Structure-activity relationships in 2,2-diphenyl-2-ethylthioacetic acid esters: Unexpected agonistic activity in a series of muscarinic antagonists. Bioorg. Med. Chem. 2001, 9, 1165-1174.
16. Eltze, M. Muscarinic M1 and M2 receptors mediating opposite effects on neuromuscular transmission in rabbit vas deferens. Eur. J. Pharmacol. 1988, 151, 205-221.
17. Caulfield, M. P.; Birdsall, N. J. M. International union of Pharmacology XVlI. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
18. Budriesi, R.; Cacciaguerra, S.; Di Toro, R.; Bolognesi, M. L.; Chiarini, A.; Minarini, A.; Rosini, M.; Spampinato, S.; Tumiatti, V.; Melchiorre, C. Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. Br. J. Pharmacol. 2001, 132, 1009-1016.
19. Waud, D. R. On the measurement of the affinity of partial agonists for receptors. J. Pharmacol. Exp. Ther. 1969, 117-122.
20. Furchgott, R. F.; Bursztyn, P. Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann. N. Y. Acad. Sci. 1967, 144, 882-889.
21. Grimm, U.; Moser, U.; Mutschler, E.; Lambrecht, G. Muscarinic receptors: Focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie 1994, 49, 711-726.
22. Felder, C. C.; Bymaster, F. P.; Ward, J.; DeLapp, N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 2000, 43, 4333-4353.
23. Kenakin, T. Ligand-selective receptor conformations revisited: The promise and the problem. Trends Pharmacol. Sci. 2003, 24, 346-354.
24. Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 1995, 16, 232-238.
25. Eglen, R. M.; Choppin, A.; Watson, N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol. Sci. 2001, 22, 409-414.
26. George, S. R.; O'Dowd, B. F.; Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discovery 2002, 1, 808-820.
27. Park, P. S.-H.; Wells, J. W. Oligomeric potential of the M2 muscarinic cholinergic receptor. J. Neurochem. 2004, 90, 537-548.
28. Gualtieri, F.; Romanelli, M. N.; Teodori, E. Eudismic analysis of a series of muscarinic ligands carrying a 1,3-oxathiolane nucleus. Chirality 1990, 2, 79-84.
29. Teodori, E.; Gualtieri, F.; Angeli, P.; Brasili, L.; Giannella, M. Resolution, absolute configuration and cholinergic enantioselectivity of (-) and (+)-c-2-methyl-r-5-[(dimethylamino)methyl]-1,3-oxathiolane t-3-oxide methiodide and related sulfones. J. Med. Chem. 1987, 30, 1934-1938.
30. Teodori, E.; Gualtieri, F.; Angeli, P.; Brasili, L.; Giannella, M.; Pigini, M. Resolution, Absolute configuration and cholinergic enantioselectivity of (+)- and (-)-cis-2-methyl-5-[(dimethylamino)methyl]-1,3-oxathiolane methiodide. J. Med. Chem. 1986, 29, 1610-1615.
31. Bruker, SMART and SAINT Software Reference Manuals; Bruker AXS Inc.: Madison, WI, 1998.
32. Sheldrick, G. M. SHELXL97: Program for crystal structure refinement: Institut für Anorganische Chemie de Universität Göttingen: Göttingen, Germany, 1998.
33. Dorje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 256, 727-733.
34. Bradford, M. M. A rapid and sensitive method for quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
35. Munson, P. J.; Rodbard, D. LIGAND: A versatile computerized approach for the characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-239.
36. Angeli, P., Brasili, L., Giannella, M., Gualtieri, F., Picchio, M. T., Teodori, E. Chiral muscarinic agonists possessing a 1,3-oxathiolane nucleus: Enantio- and tissue-selectivity on isolated preparations of guinea-pig ileum and atria and rat urinary bladder. Naunyn-Schmiedeberg's Arch. Pharmacol. 1988, 337, 241-245.
37. Angeli, P., Brasili, Gualtieri, F., Teodori, E., Enantio- and tissue-selectivity of chiral muscarinic agonists carrying a 1,3-oxathiolane nucleus. Proceedings of the International Symphosium; Sasson C., Mordechai, S., Eds.; Tel Aviv, November 30-December 4, 1986. Tel Aviv University.